213 related articles for article (PubMed ID: 33601485)
1. [Construction of artificial neural network model for predicting the efficacy of first-line FOLFOX chemotherapy for metastatic colorectal cancer].
Lin SM; Wang XJ; Huang SH; Xu ZB; Huang Y; Lu XR; Xu DB; Chi P
Zhonghua Zhong Liu Za Zhi; 2021 Feb; 43(2):202-206. PubMed ID: 33601485
[No Abstract] [Full Text] [Related]
2. Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer.
Wang X; Ghareeb WM; Zhang Y; Yu Q; Lu X; Huang Y; Huang S; Sun Y; Chi P
J Cell Physiol; 2019 Aug; 234(10):18180-18191. PubMed ID: 30859572
[TBL] [Abstract][Full Text] [Related]
3. Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.
Chen Q; Xia HW; Ge XJ; Zhang YC; Tang QL; Bi F
Asian Pac J Cancer Prev; 2013; 14(12):7421-6. PubMed ID: 24460313
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study.
Le Roy B; Tixier L; Pereira B; Sauvanet P; Buc E; Pétorin C; Déchelotte P; Pezet D; Balayssac D
PLoS One; 2016; 11(2):e0148739. PubMed ID: 26859833
[TBL] [Abstract][Full Text] [Related]
5. FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms.
Lu W; Fu D; Kong X; Huang Z; Hwang M; Zhu Y; Chen L; Jiang K; Li X; Wu Y; Li J; Yuan Y; Ding K
Cancer Med; 2020 Feb; 9(4):1419-1429. PubMed ID: 31893575
[TBL] [Abstract][Full Text] [Related]
6. Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
Moreau LC; Rajan R; Thirlwell MP; Alcindor T
Anticancer Res; 2013 Apr; 33(4):1765-8. PubMed ID: 23564831
[TBL] [Abstract][Full Text] [Related]
7. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?
Suh KW; Kim JH; Kim DY; Kim YB; Lee C; Choi S
Ann Surg Oncol; 2006 Nov; 13(11):1379-85. PubMed ID: 17009149
[TBL] [Abstract][Full Text] [Related]
8. Identification of LncRNAs Associated With FOLFOX Chemoresistance in mCRC and Construction of a Predictive Model.
Zhang Y; Xu M; Sun Y; Chen Y; Chi P; Xu Z; Lu X
Front Cell Dev Biol; 2020; 8():609832. PubMed ID: 33585448
[TBL] [Abstract][Full Text] [Related]
9. 3'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer.
Hong YS; Kim HO; Kim KP; Lee JL; Kim HJ; Lee SJ; Lee SJ; Oh SJ; Kim JS; Ryu JS; Moon DH; Kim TW
J Nucl Med; 2013 Aug; 54(8):1209-16. PubMed ID: 23804324
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
[TBL] [Abstract][Full Text] [Related]
11. Qualitative transcriptional signature for predicting pathological response of colorectal cancer to FOLFOX therapy.
He J; Cheng J; Guan Q; Yan H; Li Y; Zhao W; Guo Z; Wang X
Cancer Sci; 2020 Jan; 111(1):253-265. PubMed ID: 31785020
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial.
Wang H; Huang L; Gao P; Zhu Z; Ye W; Ding H; Fang L
BMJ Open; 2020 Feb; 10(2):e030738. PubMed ID: 32051297
[TBL] [Abstract][Full Text] [Related]
13. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
15. Impact of diabetes comorbidity on the efficacy and safety of FOLFOX first-line chemotherapy among patients with metastatic colorectal cancer: a pooled analysis of two phase-III studies.
Abdel-Rahman O
Clin Transl Oncol; 2019 Apr; 21(4):512-518. PubMed ID: 30182209
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
[TBL] [Abstract][Full Text] [Related]
17. Identification of the biomarkers for the prediction of efficacy in first-line chemotherapy of metastatic colorectal cancer patients using SELDI-TOF-MS and artificial neural networks.
Yuan Y; Tan CW; Shen H; Yu JK; Fang XF; Jiang WZ; Zheng S
Hepatogastroenterology; 2012; 59(120):2461-5. PubMed ID: 22497949
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
Yoshida Y; Hasegawa J; Nishimura J; Hirota M; Kim Y; Nezu R
Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
20. A liquid biopsy signature of circulating extracellular vesicles-derived RNAs predicts response to first line chemotherapy in patients with metastatic colorectal cancer.
Yang Y; Zhang J; Zhang W; Wang Y; Zhai Y; Li Y; Li W; Chang J; Zhao X; Huang M; Geng Q; Yang Y; Gong Z; Yu N; Shen W; Li Q; Huang S; Guo W
Mol Cancer; 2023 Dec; 22(1):199. PubMed ID: 38062470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
